Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioAge Labs (BIOA) EBITDA (2024 - 2025)

BioAge Labs (BIOA) has disclosed EBITDA for 2 consecutive years, with -$25.9 million as the latest value for Q4 2025.

  • Quarterly EBITDA fell 22.92% to -$25.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$80.6 million through Dec 2025, down 13.45% year-over-year, with the annual reading at -$80.6 million for FY2025, 13.44% down from the prior year.
  • EBITDA hit -$25.9 million in Q4 2025 for BioAge Labs, down from -$20.1 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$12.9 million in Q1 2025 to a low of -$25.9 million in Q4 2025.